PCSK9 Axis-Targeting Pseurotin A as a Novel Prostate Cancer Recurrence Suppressor Lead-Reference-Cited by-同舟云学术

PCSK9 Axis-Targeting Pseurotin A as a Novel Prostate Cancer Recurrence Suppressor Lead

Published:2021-10-05 Issue:6 Volume:4 Page:1771-1781
ISSN:2575-9108
Container-title:ACS Pharmacology & Translational Science
language:en
Short-container-title:ACS Pharmacol. Transl. Sci.

Author:

Abdelwahed Khaldoun S.¹,Siddique Abu Bakar¹,Qusa Mohammed H.¹,King Judy Ann²,Souid Soumaya¹,Abd Elmageed Zakaria Y.³,El Sayed Khalid A.¹^ORCID

Affiliation:

1. School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, 1800 Bienville Drive, Monroe, Louisiana 71201, United States

2. Department of Pathology and Translational Pathobiology, LSU Health Shreveport, 1501 Kings Highway, Shreveport, Louisiana 71103, United States

3. Department of Pharmacology, Edward Via College of Osteopathic Medicine, University of Louisiana at Monroe, Monroe, Louisiana 71203, United States

Funder

Biomedical Research Foundation of Northwest Louisiana

Publisher

American Chemical Society (ACS)

Subject

Pharmacology (medical),Pharmacology

Link

https://pubs.acs.org/doi/pdf/10.1021/acsptsci.1c00145

Reference39 articles.

1. Cancer Statistics, 2021

2. Prediction of Pathological Stage in Patients with Prostate Cancer: A Neuro-Fuzzy Model

3. Novel targeted therapeutics for metastatic castration-resistant prostate cancer

4. Variation in the Definition of Biochemical Recurrence in Patients Treated for Localized Prostate Cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel Report and Recommendations for a Standard in the Reporting of Surgical Outcomes

5. Risk of Prostate Cancer–Specific Mortality Following Biochemical Recurrence After Radical Prostatectomy

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The multifaceted role of PCSK9 in cancer pathogenesis, tumor immunity, and immunotherapy;Medical Oncology;2024-07-15

2. Dyslipidemia, lipid-lowering agents and neuroendocrine neoplasms: new horizons;Endocrine;2024-03-20

3. Association between Immune Checkpoint Inhibitors and Atherosclerotic Cardiovascular Disease Risk: Another Brick in the Wall;International Journal of Molecular Sciences;2024-02-21

4. Targeting PCSK9 reduces cancer cell stemness and enhances antitumor immunity in head and neck cancer;iScience;2023-06

5. Inhibition of proprotein convertase subtilisin-like kexin type 9 (PCSK9) potentiates anti-angiogenic therapy in colorectal cancer liver metastases;2023-05-29